Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novaferon plus standard therapy for COVID-19
ChiCTR2000029573Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Feb 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of novaferon in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Time to SARS-CoV-2 RNA negative conversion. Started Feb 2020; status: recruiting.
02
Drugs
novaferon
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000029573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029573.